CAPN1 Protein
Introduction <table class="infobox infobox-protein">
Capn1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gene: [CAPN1](/proteins/capn1-protein) [@liu2008]
UniProt: P07384 [@baudry2013]
Molecular Weight: ~82 kDa (catalytic subunit) [@yamashima2019]
Subcellular Localization: Cytosol, membrane-associated [@wang2018]
Protein Family: Calpain family, cysteine proteases [@czogalla2019]
Overview ...
CAPN1 Protein
Introduction <table class="infobox infobox-protein">
Capn1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gene: [CAPN1](/proteins/capn1-protein) [@liu2008]
UniProt: P07384 [@baudry2013]
Molecular Weight: ~82 kDa (catalytic subunit) [@yamashima2019]
Subcellular Localization: Cytosol, membrane-associated [@wang2018]
Protein Family: Calpain family, cysteine proteases [@czogalla2019]
Overview CAPN1 (Calpain 1), also known as μ-calpain or μ-calcium-activated neutral protease (μCANP), is a calcium-dependent cysteine protease that mediates limited proteolysis of various substrates. Calpain 1 is heterodimeric, consisting of a catalytic large subunit (CAPN1, ~80 kDa) and a regulatory small subunit (CAPNS1, ~28 kDa). The protease is ubiquitously expressed and plays critical roles in both normal cellular processes including signal transduction, cell cycle progression, and synaptic plasticity, as well as pathological processes including [apoptosis](/entities/apoptosis) and neurodegeneration. CAPN1 is activated by micromolar calcium concentrations and requires calmodulin for full activity. Unlike calpain 2 (m-calpain), calpain 1 is activated at lower calcium concentrations, making it particularly relevant in physiological signaling. [@ray2014]
Protein Structure Calpain 1 is a heterodimer composed of: [@huang2001]
Large Subunit (CAPN1, ~80 kDa)
N-terminal catalytic domain (PC1) with cysteine protease active site
penta-EF-hand (PEF) domains (PC2) for calcium binding
C-terminal hydrophobic domain for membrane association
Small Subunit (CAPNS1, ~28 kDa)
Glycine-rich hydrophobic domain
PEF domain for dimerization with large subunit
The protease contains:
Active site cysteine (C105)
Calcium-binding EF-hand motifs
Autolysis site for activation
Molecular Function
Proteolytic Activity Calpain 1 catalyzes limited, non-destructive proteolysis:
Cleaves after specific sequences, not random degradation
Targets cytoskeletal proteins, signaling molecules, transcription factors
Regulates protein function through controlled cleavage
Substrate Specificity Key neuronal substrates include:
Spectrin (membrane cytoskeletal protein)
[Tau](/proteins/tau) (microtubule-associated protein)
Amyloid precursor protein ([APP](/entities/app-protein))
p35/p39 ([CDK5](/proteins/cdk5-protein) regulatory subunits)
[NMDA](/entities/nmda-receptor) receptor subunits
Synaptic proteins (SNAP-25, synaptotagmin)
Calcium Regulation
Basal activity very low in absence of calcium
Calcium binding induces conformational change
Autolysis at ~1 μM Ca²⁺ activates the protease
Calmodulin binding enhances activation
Role in Neurodegeneration
Alzheimer's Disease
Overactivation by [Aβ](/proteins/amyloid-beta) oligomers leads to synaptic damage
Cleaves [tau](/proteins/tau), generating toxic fragments
Mediates Aβ-induced neuronal apoptosis
Contributes to cytoskeletal degradation
Calpain-[cdk5](/proteins/cdk5-protein) pathway dysregulation
Parkinson's Disease
Activated by dopaminergic neuron stress
Cleaves [alpha-synuclein](/mechanisms/alpha-synuclein), potentially promoting aggregation
Mediates mitochondrial dysfunction-induced cell death
Contributes to Lewy body formation
Amyotrophic Lateral Sclerosis (ALS)
Activated in motor [neurons](/entities/neurons) by excitotoxicity
Cleaves mutant SOD1, generating toxic fragments
Mediates excitotoxic neuronal death
Contributes to cytoskeletal disruption
Stroke and Traumatic Brain Injury
Rapidly activated following ischemia
Mediates excitotoxic cell death
Contributes to blood-brain barrier breakdown
Target for neuroprotective therapy
Huntington's Disease
Calpain activation by mutant [huntingtin](/proteins/huntingtin-protein)
Generates toxic [huntingtin](/genes/htt) fragments
Contributes to transcriptional dysregulation
Expression Pattern CAPN1 is widely expressed in:
Cerebral [cortex](/brain-regions/cortex) (pyramidal neurons)
[Hippocampus](/brain-regions/hippocampus) (all regions)
Cerebellum (Purkinje cells)
Basal ganglia
Spinal cord motor neurons
Expression is particularly high in regions with high synaptic activity.
Therapeutic Implications
Inhibitors
Calpain inhibitors : Leupeptin, ALLN, MDL-28170Calpain-specific inhibitors : Calpeptin, PD150606Endogenous inhibitor : CalpastatinClinical Approaches
[Blood-brain barrier](/entities/blood-brain-barrier) penetrating inhibitors in development
Targeting calpain-10 for neurodegeneration
Gene therapy approaches
Research Directions
Biomarkers of calpain activation (spectrin breakdown products)
Neuroprotective strategies using calpain inhibition
Animal Models
Capn1 knockout mice : Viable but with defects in platelet functionTransgenic overexpression models : Reveal neuronal vulnerabilityConditional knockouts : Tissue-specific functionsBackground The study of Capn1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
[CAPN1 Gene](/genes/capn1)
Calpain System
[Calcium Signaling](/mechanisms/calcium-signaling)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
Show full description